Yasushi Hiramatsu

Himeji, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Tumor flare reaction during epcoritamab treatment in refractory diffuse large B-cell lymphoma

Tumor flare reaction during epcoritamab treatment in refractory diffuse large B-cell lymphoma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 04, 2026

Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma.

Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: January 28, 2026

WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy.

WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy.

Journal: Annals of hematology

Published: December 01, 2025

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Journal: Haematologica

Published: November 18, 2025

A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE.

A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE.

Journal: International journal of hematology

Published: November 14, 2025

A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis.

A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis.

Journal: Therapeutic advances in hematology

Published: September 04, 2025

Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.

Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.

Journal: International journal of hematology

Published: August 19, 2025

Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.

Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.

Journal: International journal of hematology

Published: April 17, 2025

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

Journal: Cancer science

Published: September 27, 2024

Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.

Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: May 15, 2024

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.

Journal: International journal of hematology

Published: January 03, 2024

Primary Thyroid Lymphoma: Clinical Factors Predicting the Possibility of Diffuse Large B-Cell Lymphoma.

Primary Thyroid Lymphoma: Clinical Factors Predicting the Possibility of Diffuse Large B-Cell Lymphoma.

Journal: Ear, nose, & throat journal

Published: December 11, 2023

Showing 1-12 of 34

Last Updated: 09/26/2026